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Abstract 
Background:.To compare intranasal Fluticasone 
furoate spray with oral anti-histamine and anti-
leukotriene therapy in allergic rhinitis in terms of 
change in mean nasal symptoms score.  
 Methods: In this randomized control trial two 
groups were selected having 40 patients in each 
group. To group (A) cetirizine 10 mg plus 
montelukast 10 mg once daily was prescribed  and to 
group (B) Fluticasone Furoate nasal spray 110 mcg 
once daily was prescribed for 6 months.Patients were 
called for follow up visits 4 times, 1st after 2 weeks 
then after every two months. On every follow-up 
visit .Total nasal symptoms scores were registered. 
Final outcome was measured on 4th visit. 
Results: After six months follow up, the minimum 
total nasal symptom score was calculated as 0.50 and 
maximum total nasal symptom score was calculated 
as 2.88 with mean + SD  as 1.62 + 0.69. There were 
45% male and 55% were female. In group A, the 
mean +SD was 2.21 + 0.38 whereas in group B the 
mean +SD was 1.04 + 0.33. Significant difference was 
found between study groups for the AR having p-
value 0.001.Significant difference of mean change in 
symptoms was found in both groups with p-value = 
0.000 in age group < 40 years. In age group > 40 years, 
significant difference of mean change in symptoms 
was found in both groups with p-value = 0.000. 
Conclusion: Fluticasone furoate nasal spray was 
more effective than combined oral anti-histamines 
and leukotriene receptor antagonists in allergic 
rhinitis. 
Key Words: Fluticasone Furoate, Cetirizine, 
Montelukast, Allergic Rhinitis 
 
Introduction 
Allergic rhinitis (AR) is type I hypersensitivity 
consisting of attacks of sneezing, rhinorrhoea, nasal 
blockade, and irritation of the eyes, nose, and palate. It 
is also characterized with postnasal drip, prickliness, 
cough and tiredness. When an individual is exposed to 
allergen he/she produces allergen-specific IgE. When 
this allergen is inhaled subsequently, IgE antibodies 
are linked on cell surface, which results in activation of 
cells and so symptoms of AR appear. 1 For satisfactory 
symptom control,mostly patients having allergic 
rhinitis need medications, supplement to avoidance of 
allergens. Patients extensively self-treat because 
mostly medicines become available without a 
prescription and the side effects of these antiallergy 
medicines are predominantly unwarranted sedation 
and anticholinergic sequels which are significant.2 The 
existing encounter faced by doctors is to reassure that 
patients having acute AR are satisfactorily treated with 
medicines that do not trigger unnecessary side effects.3  
Atopic individuals usually react by producing 
allergen-specific IgE when exposed to an allergen. 
These antibodies get attached cells in respiratory 
mucosa to receptors on the mast cells and to basophils 
in the peripheral blood. Afterwards when the similar 
allergen is inhaled, IgE antibodies get connected to the 
cell surface by allergen, resulting in stimulation of the 
cell. Mast cells release preformed and granule-
associated chemical mediators, which lead to allergic 
rhinitis symptoms.4 
First line treatment for AR is  oral anti-histamines5.AR 
 symptoms appear by an interaction between inhaled 
allergens and antibodies on mast cells which are 
positioned in upper airway tract.6 It is probable to 
attain faster relief of symptoms by direct delivery of 
medicines to the nasal tissues. As a next line therapy 
oral anti-histamines and intranasal steroids, in 
combination, are usually presscribed.Intra-nasal 
steroids are suggested as the most appropriate 
medication for AR, widely covering symptoms of 
allergy, with the benefits of mono-therapy, such as 
better patient compliance, cost-effectiveness, and 
decreased side effects profile7. Specific medications 
include fluticasone propionate, mometasone furoate, 
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triamcinolone, beclomethasone, fluticasone furoate8. 
These drugs differ with regard to the bioavailability, 
frequency of doses, the spray device, and cost. 
Fluticasone propionate and Mometasone furoate have 
almost comparable and very low systemic 
bioavailability when administered intra-nasally even 
at high-dose.9 Steroids which are used topically, alter 
the nasal environment in terms of Mucociliary 
clearance.10   
Montelukast used with antihistamines such as 
cetirizine or loratadine has usually resulted in more 
effectiveness than when these medicines are used 
alone.11 Montelukast has a favourable safety profile. 
Montelukast is effective in decreasing congestion and 
mucus production.12 According to studies, 
Desloratadine-montelukast combination therapy 
causes decrease in nasal obstruction.13 Pullerits and his 
colleagues assessed the effects of leukotriene 
antagonist,nasal steroids, and a grouping of 
antihistamine and leukotriene antagonist in the 
management of periodic allergic rhinitis. Result of 
their study showed mean symptoms score with 
Fluticasone propionate local nasal spray and combined 
antileukotriene and antihistamine as 1.1±0.5 and 
1.5±0.4 respectively.  They concluded that intranasal 
steroids are better than combined antileukotriene and 
antihistamine in controlling nasal symptoms in allergic 
rhinitis.14 
AR Rhinitis is one of the commonest ailment round the 
world and also in Pakistan. According to a study, AR 
is most common allergic disease in Pakistan (24.62%). 
and in Pakistan it is very common in Islamabad and 
KPK.15 In two studies of Gill MZ, he concluded that 
intra-nasal steroids improve mucociliary clearance and 
improve the patient quality of life.16    
 
Patients and Methods  
A randomized control trial with 80 patients was 
conducted at Capital Hospital Islamabad from  
December,2015 to December 2016 after approval from 
the ethical committee. Patients were selected with age 
range between 25 to 60 years and both male and 
female candidates. Patients having symptoms at 
screening, i.e., TNSS >6 with any one combination of 
nasal blockage, runny nose, nasal itching, sneezing 
and difficulty in sleep, were included. Exclusion 
criteria for this study was patients having non-allergic 
rhinitis, nasal blockage due to DNS or any other 
structural abnormalities, nasal polyps, hyper-
sensitivity to intra-nasal steroids, cetirizine, 
Montelukast, known hypertensive, immuno-
compromised, known diabetics and patients on oral 
steroids for any other condition. Patients (n=80) were  
divided into two groups. To group A (having 40 
patients) plus montelukast 10 mg once and cetirizine 
10 mg once daily daily was prescribed for 6 months 
and to group B (having 40 patients) Fluticasone 
Furoate nasal spray 110 mcg once daily (27.5 mcg per 
spray) i.e. 2 sprays in each nostril daily was prescribed 
for 6 months. Baseline nasal symptom score was 
calculated on first visit. Patients were called for follow 
up visits 4 times, 1st after 2 weeks then after every two 
months. On every follow-up visits total nasal 
symptoms scores were registered on questionnaire. 
Sum of the nasal symptoms score were calculated on 
every visit. Final outcome was measured on 4th visit 
i.e. after 6 months of starting therapy. Quantitative 
variables were mean score (at baseline, at 6 months 
and mean change)and age measured as mean ±SD. 
Mean symptoms score change was measured and was 
compared between two groups by independent 
sample t-test with level of significance of ≤0.05. Gender 
and age were controlled by stratification. Post 
stratification independent sample t-test was applied. 
 
Results 
Age range was from 25 years to 56 years (Mean ± SD: 
38.34 ± 9.59 years). The minimum total nasal symptom 
score was calculated as 2.00 and maximum total nasal 
symptom score as 3.33 (Mean ± SD:2.59 ± 0.36). After 
six months follow up, the minimum total nasal 
symptom score was 0.50 and maximum total nasal 
symptom score as 2.88 with mean ±standard deviation 
as 1.62 ± 0.69. There were 36 (45%) male and 44 (55%) 
were female. There were forty patients in each study 
group (Table 1). In group A (cetirizine plus 
montelukast), the mean ± standard deviation was 
observed as 2.21 ±0.38 and in group B (Fluticasone 
Furoate nasal spray), the mean ± standard deviation 
was observed as 1.04 ± 0.33 (Table 2). Statistically 
significant difference was found by using independent 
sample t-test between study groups for the allergic 
rhinitis having p-value 0.001 (Table 3).By using 
independent sample t-test, significant difference of 
mean change in symptoms was found in both groups 
with p-value = 0.000 in males. In females, significant 
difference in symptoms was found in both groups with 
p-value = 0.000. Significant difference of mean change 
in symptoms was found in both groups with p-value = 
0.000 in age group of < 40 years. In age group of > 40 
years, significant difference of mean change in 
symptoms was found in both groups with p-value = 
0.000 (Table 4 &5). 
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Table.1:  Descriptive statistics (overall) (n=80) 
 Minimum Maximum Mean 
Std. 
Devia-
tion 
Age 25.00 56.00 38.34 9.59 
Total Nasal 
Symptom 
Score 
2.00 3.33 2.59 0.36 
Total Nasal 
Symptom 
Score Follow 
up 
.50 2.88 1.62 0.69 
Table.2: Group-wise descriptive statistics 
 
Medicine 
Group 
Mean Std. Deviation 
Age 
Group A 38.33 9.66 
Group B 38.35 9.64 
Total Nasal 
Symptom Score 
Group A 2.66 .38 
Group B 2.54 .33 
Total Nasal 
Symptom Score 
Follow up 
Group A 2.21 .38 
Group B 1.04 .33 
Table.3 Difference of mean symptom score 
between study groups 
Medicine 
Group 
Mean 
Std. 
Deviation 
P-Value 
Group A 2.21 0.38 
0.001 
Group B 1.04 0.33 
Independent t-test applied 
Table.4 Stratification of mean change in 
symptoms score with respect to gender 
Gender 
Medicine 
Group 
n 
Mean + Std. 
Deviation 
P-value 
Male 
Group A 18 2.22 + 0.38 
0.000 
Group B 18 1.18 + 0.34 
Female 
Group A 22 2.19 + 0.39 
0.000 
Group B 22 0.93 + 0.29 
Independent t-test applied 
Table.5  Stratification of mean change in symptoms 
score with respect to age 
Age  
Medicine 
Group 
n 
Mean + Std. 
Deviation 
P-value 
< 40 Years 
Group A 20 2.23 + 0.38 
0.000 
Group B 20 1.07 + 0.32 
> 40 Years 
Group A 20 2.18 + 0.39 
0.000 
Group B 20 1.02 + 0.36 
Independent t-test applied 
Discussion 
Allergic Rhinitis (AR) is IgE mediated inflammation 
consisting of attacks of rhinorrhoea, sneezing, nasal 
obstruction and itching of the nose, eyes and palate. It 
is characterized by postnasal drip, irritability,cough, 
and lethargy.15,6,13 
Research done by Varshney et al. showed that patients 
(58% males median age 32 years) with symptom 
duration of 24 months chose fluticasone propionate vs 
ciclesonide nasal spray (55.41% vs. 25.68%, p=0.007) 
and also with regard to calming feel, qualities of scent 
and nasal irritation. It was found that there was no 
statistically significant difference in immediate 
effectiveness.7 Berger et al. compared 220 microgram 
intranasal aqueous triamcinolone acetonide (TAA AQ) 
daily with 200 microg. fluticasone propionate (FP) 
.Decreases in patients symptoms and total nasal 
symptom score were statistically significant as 
compared to baseline and were equivalent between 
treatments. Intranasal fluticasone propionate and 
aqueous triamcinolone acetonide were similarly 
effective in relieving symptoms of seasonal allergic 
rhinitis.17 
In a study by Baroody et al total  nasal symptom score 
was lower with the combination matched with 
treatment with placebo and oxymetazoline alone (p = 
.04)over the 4 weeks of treatment. When acoustic 
rhinometry was competed between the groups, the 
combination showed significantly higher nasal volume 
(p< .03) compared with both placebo and 
oxymetazoline alone at the end of 4 weeks of 
treatment. Quality of life data revealed no significant 
differences between the groups. Peak flow showed a 
non-significant progress with the groups on 
fluticasone furoate. Rhinitis medicamentosa was not 
evident in the study.18Result from a previous study 
showed  that intranasal steroids are better than 
combined antileukotriene and antihistamine in 
controlling nasal symptoms in allergic rhinitis.14 In 
another research, Azelastine showed a statistically 
significant improvement in TNSS (Total nasal 
symptom score)as compared to placebo at all time 
points from 15 minutes through 6 hours post dose. 
Azelastine, loratadine and cetirizine reduced TNSS as 
compared to placebo with an onset of action of 15 (p < 
0.001), 60 (p = 0.015), and 75 (p = 0.034) minutes, 
respectively19.In previous research of Gill et al. the 
measures of basophil, eosinophil and neutrophil 
counts and mucociliary clearance were significantly 
superior in mometasone furoate than in placebo 
managed patients. Correspondingly, within-treatment 
statistically significant improvements were formed by 
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mometasone furoate but not by placebo sprays for the 
levels of eosinophilic cationic protein, albumin and 
tryptase, NAR, and odour documentation. Significant 
positive correlations were established between NAR 
and nasal stuffiness and between eosinophils, 
neutrophils and basophils, and both eosinophilic 
cationic protein and albumin.20 
 
Conclusion 
Fluticasone furoate nasal spray is more efficient than 
combined oral anti-histamines and leukotriene 
antagonists in treating allergic rhinitis. 
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